ClinicalTrials.gg
CompletedNCT04542057Updated Oct 16, 2023Results posted

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

A Phase 3 interventional study of Ensifentrine and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma plc. Completed at 130 sites in 10 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-16.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
790
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
2nd of 15
790 · median 79
Started
2020
with 1 other
Phase 3
5 of 15
1 open now
Registered
8th of 15
by date
Lead sponsor
9 of 15
Verona Pharma plc

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving informed consent indicating that they understand the purpose of the study and study procedures and agree to comply with the requirements and restrictions listed in the informed consent form (ICF).

    Age and Sex

  2. Age: Patient must be 40 to 80 years of age inclusive, at the time of Screening.
  3. Sex:

    • Males are eligible to participate if they agree to use as described in the contraceptive guidance from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication.
    • Females are eligible to participate if they are not pregnant, not breastfeeding, and at least one of the following conditions apply:

      1. Not a woman of (WOCBP). Or
      2. A WOCBP who agrees to follow the contraceptive guidance from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication.

    Smoking History

  4. Smoking History: Current or former cigarette smokers with a history of cigarette smoking ≥10 pack years at Screening (Visit 0) [number of pack years = (number of cigarettes per day / 20) × number of years smoked (eg, 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Pipe and/or cigar use cannot be used to calculate pack-year history. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 0. Smoking cessation programs are permitted during the study.

    Diagnosis, Symptoms, Severity and Maintenance Therapy

  5. COPD Diagnosis: Patients with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli BR, 2004) with symptoms compatible with COPD.
  6. COPD Symptoms: A score of ≥2 on the Modified Medical Research Council (mMRC) Dyspnea Scale.
  7. COPD Severity:

    1. Pre- and Post-albuterol/salbutamol /FVC ratio of \<0.70.
    2. Post-albuterol/salbutamol FEV1 ≥30 % and ≤70% of predicted normal calculated using the National Health and Nutrition Examination Survey III.
  8. Maintenance Therapy: Patients on no maintenance/background therapy or patients on stable maintenance LAMA or LABA therapy are eligible. Patients taking maintenance LAMA or LABA therapy must demonstrate stable use of the maintenance LAMA or LABA therapy for at least 3 months prior to Screening and agree to continue use for the duration of the study. Background maintenance LAMA or LABA bronchodilator therapy will be capped at 50% of patients.

    Other Requirements for Inclusion

  9. Capable of withholding SABAs for 4 hours prior to initiation of any spirometry. Patients in the maintenance LAMA or LABA therapy stratum must be capable of withholding Twice-Daily maintenance LAMA or LABA for 24 hours and Once-Daily maintenance LAMA or LABA for 48 hours prior to initiation of any spirometry.
  10. Capable of using the study nebulizer correctly and complying with all study restrictions and procedures.
  11. Ability to perform acceptable spirometry in accordance with ATS/ERS guidelines.

Randomization Criteria Criteria for Inclusion at Randomization

  1. Symptoms of COPD: A score of ≥2 on the mMRC Dyspnea Scale.
  2. Completion of the e-Diary at least 5 of the last 7 days of the Run-in period.

Exclusion criteria

Exclusion Criteria:

Current Condition or Medical History

  1. History of life-threatening including Intensive Care Unit admission and/or requiring intubation.
  2. Hospitalizations for COPD, pneumonia, or Corona Virus Disease 2019 (COVID-19) in the 12 weeks prior to Screening and/or a positive COVID-19 test result indicating an active infection at Screening. Patients with COVID-19 antibodies from a previous exposure with no active infection are not excluded.
  3. COPD exacerbation requiring oral or parenteral within 3 months of Screening.
  4. Previous lung resection or lung reduction surgery within 1-year of Screening.
  5. Long term oxygen use defined as oxygen therapy prescribed for greater than 12 hours per day. As needed oxygen use (≤12 hours per day) is not exclusionary.
  6. Pulmonary rehabilitation, unless such treatment has been in a stable maintenance phase for 4 weeks prior to Visit 1 and remains stable during the study.
  7. Lower respiratory tract infection within 6 weeks of Screening.
  8. Other respiratory disorders including, but not limited to, a current diagnosis of asthma, active tuberculosis, lung cancer, sarcoidosis, lung fibrosis, interstitial lung diseases, unstable sleep apnea, known alpha-1 antitrypsin deficiency, core pulmonale, pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary diseases.
  9. Major surgery (requiring general anesthesia) in the 6 weeks prior to Screening, lack of full recovery from surgery at Screening, or planned surgery through the end of the study.
  10. Historical or current evidence of clinically significant cardiovascular disease defined as any disease that in the opinion of the Investigator would put the safety of the patient at risk through participation or which could affect the efficacy or safety analysis if the disease/condition were to exacerbate during the study, including, but not limited to:

    • Myocardial infarction or unstable angina within 6 months prior to Screening.
    • Unstable or life-threatening cardiac arrhythmia requiring intervention within 3 months prior to Screening.
    • Diagnosis of Class III and Class IV heart failure.
  11. Chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the Investigator believes are clinically significant.
  12. Unstable liver disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).
  13. History of or current of any organ system, treated or untreated within the past 5 years, except for localized basal or squamous cell carcinoma of the skin.
  14. Findings on physical examination that an investigator considers to be clinically significant at Screening.

    Prior/Concomitant Therapy

  15. Use of prohibited medications within the time intervals

    History or Suspicion of Drug or Alcohol Abuse

  16. Current or history of past drug or alcohol abuse within the past 5 years.

    Laboratory and Other Diagnostic Parameters

  17. (eGFR) \<30 mL/min. The Chronic Kidney Disease Epidemiology Collaboration Creatinine (2009) calculation will be used.
  18. (ALT) ≥ 2 x (ULN), alkaline phosphatase and/or > 1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  19. antibody:

    • Positive findings for both Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (anti-HBc) are excluded, as this indicates acute or chronic infection.
    • Negative findings for HBsAg and Hepatitis B surface antibody (anti-HBs) but positive findings for anti-HBc are excluded as this may indicate current or resolving infection.
    • Positive findings for anti-HBc and anti-HBs but negative findings for HBsAg are not excluded, as this indicates immunity due to natural infection.
    • Positive findings for anti-HBs but negative findings for HBsAg and anti-HBc are not excluded, as this indicates immunity due to hepatitis B vaccination.
  20. antibody positive.
  21. Any other abnormal hematology, biochemistry, or viral serology deemed by an investigator to be clinically significantly abnormal. Abnormal chemistry and/or hematology may be repeated during Screening.
  22. Chest X-ray (CXR; posterior-anterior) at Screening, or in the 12 months prior to Screening with clinically significant abnormalities not attributable to COPD. If a CXR within the past 12 months is not available but a computerized tomography (CT) scan within the same time period is available, the CT scan may be reviewed in place of a CXR. For subjects in Germany, if a CXR or CT scan is not available in the 12 months prior to Screening, the subject is not eligible for the study.
  23. (ECG) finding that is significantly abnormal on the 12-lead ECG obtained at Screening.

    Other Exclusions

  24. Use of an experimental drug within 30 days or 5 half-lives of Screening, whichever is longer, and/or participation in a study treatment-free follow-up phase of a clinical trial within 30 days prior to Screening.
  25. Use of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical trial within 30 days prior to Screening.
  26. Intolerance or to albuterol/salbutamol or ensifentrine (RPL554) or any of its /components.
  27. Prior receipt of blinded study medication in an ensifentrine (RPL554) study.
  28. Affiliation with the investigator site, including an Investigator, Sub-Investigator, study coordinator, study nurse, other employee of participating investigator or study site or a family member of the aforementioned.
  29. Inability to read, understand, and/or complete questionnaires (in the opinion of the Investigator).
  30. A disclosed history or one known to the Investigator of significant non-compliance in previous studies or with prescribed medications.
  31. Any other reason that the Investigator considers makes the patient unsuitable to participate.

Criteria for Exclusion from Randomization

  1. COPD exacerbation or lower respiratory tract infection between Screening and Randomization (defined as use of any additional treatment other than current treatment and rescue medication and/or emergency department or hospital visit). Patients with a severe COPD exacerbation that requires hospitalization may not be rescreened.
  2. Positive COVID-19 result at Screening or between Screening and Randomization.
  3. Prohibited medication use between Screening Visit 0 and Visit 1.
  4. Significantly abnormal ECG finding on the 12-lead ECG obtained at Screening as assessed by the investigator or site medical doctor/medically qualified person or on the pre-dose (prior to randomization) ECG obtained at Visit 1. In the event that the central ECG reviewer discovers a significant ECG abnormality on the Visit 1 ECG, the patient will be discontinued.
  5. Did not meet one or more of the Inclusion Criteria or met one or more of the Exclusion Criteria.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
790 participants (actual)

Study arms

  • Experimental
    Arm 1

    Ensifentrine Nebulized Suspension; 3 mg twice daily for 24 weeks

    Drug: Ensifentrine

  • Placebo comparator
    Arm 2

    Ensifentrine Placebo Nebulized Solution; twice daily for 24 weeks

    Drug: Placebo

Interventions

  • Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks

  • DrugPlacebo

    Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks

06

What researchers measure

Primary outcomes

  1. Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Average FEV1 AUC0-12h was defined as AUC over 12 hours of the FEV1, divided by 12 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.

    Time frame: Baseline (40 minutes before first administration on Day 1) and Week 12

Secondary outcomes

  1. LS Mean Change From Baseline FEV1 to Peak FEV1 at Day 1 and Weeks 6, 12 and 24

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Peak FEV1 is the maximum value in the 4 hours after dosing. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (40 minutes before first administration on Day 1), post-dose on Day 1, Weeks 6, 12, and 24

  2. LS Mean Change From Baseline to the Mean Weekly Evaluating-Respiratory Symptoms (E-RS) Total Score at Weeks 6, 12 and 24

    The E-RS scale consists of 11 questions, with 3 sub-domains of: breathlessness, cough and sputum, and chest symptoms. The E-RS sub-domain score was calculated as the sum from the relevant questions. The E-RS total score was derived as the sum of the raw scores of the 11 items ranging from 0 to 40. Higher scores indicates severe respiratory symptoms. Scores were derived weekly as the mean over 7 days prior to the visit, using only days where data was recorded. The E-RS was collected daily by electronic diary (e-diary). Baseline is the mean over the 7 days prior to the first intake of study medication, using only days where data was recorded.

    Time frame: Baseline (average of 7 days before first administration on Day 1) and Weeks 6, 12, and 24

  3. LS Mean Change From Baseline in the St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 6, 12 and 24

    The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Score ranging from 0 to 100 and higher scores indicated a worse outcome. Baseline is the score calculated on Day 1 prior to 4 hour post-dose spirometry.

    Time frame: Baseline (40 minutes before first administration on Day 1) and Weeks 6, 12, and 24

  4. LS Mean Change From Baseline FEV1 to Morning Trough FEV1 at Weeks 6, 12 and 24

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Morning trough FEV1 was the last value collected prior to the morning dose. Baseline FEV1 is the mean of the two measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (40 minutes before first administration on Day 1) and Weeks 6, 12, and 24

  5. LS Mean Change From Baseline in Average FEV1 Area Under the Curve Over 4 Hours (AUC0-4h) at Day 1 and Weeks 6, 12 and 24

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Average FEV1 AUC0-4h was defined as area under the curve over 4 hours of the FEV1, divided by 4 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (40 minutes before first administration on Day 1), post-dose on Day 1, Weeks 6, 12, and 24

  6. Percentage of SGRQ Responders at Weeks 6, 12 and 24

    The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Responder was a patient with an improvement from baseline in SGRQ total score of 4 or more. Percentage of SGRQ responders are reported.

    Time frame: Weeks 6, 12 and 24

  7. LS Mean Change From Baseline to the Mean Weekly Rescue Medication Use at Weeks 6, 12 and 24

    Use of rescue medication (albuterol/salbutamol) per week was calculated as the LS mean use daily over 7 days. Daily rescue medication use was collected in an e-diary throughout the study. Baseline is the mean over the 7 days prior to the first intake of study medication, calculated as the sum of puffs taken, divided by number of days data has been recorded.

    Time frame: Baseline (average of 7 days before first administration on Day 1) and Weeks 6, 12, and 24

  8. LS Mean Transition Dyspnea Index (TDI) Questionnaire Total Score at Weeks 6, 12 and 24

    The TDI is a questionnaire that focused on 3 sub-domains: functional impairment, magnitude of task and magnitude of effort. Sub-domain score was calculated as the sum from the related questions. Total score was calculated as the sum of the sub-domain scores. The TDI measures the change in dyspnea severity from the baseline as measured by the baseline dyspnea index. It was rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement). Higher scores indicate better outcome. Change from baseline was assessed with the Baseline Dyspnea Index.

    Time frame: Weeks 6, 12 and 24

  9. LS Mean Change From Baseline FEV1 to Evening Trough FEV1 at Week 12

    Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Evening trough FEV1 was the value collected at 12 hours post-morning dose and prior to the evening dose. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

    Time frame: Baseline (40 minutes before first administration on Day 1) and Week 12

07

Results

Posted Jul 24, 2023

Participant flow

This Phase 3, randomized, double-blind, placebo-controlled study was conducted in patients with moderate to severe chronic obstructive pulmonary disease (COPD) at 130 study centers in Belgium, Bulgaria, Canada, Denmark, Estonia, Hungary, Poland, Slovakia, Spain, United States of America between 22 September 2020 and 06 July 2022. Patients were randomized in a 5:3 ratio, stratified by smoking status and background medication use, manner to receive either ensifentrine or placebo.

Participant flow — Overall Study
MilestoneEnsifentrinePlacebo
Started499291
Received treatment498291
Completed393218
Not completed10673
Withdrew: Death31
Withdrew: Copd exacerbation withdrawal criteria56
Withdrew: Coronavirus disease 2019 (covid-19)107
Withdrew: Adverse event156
Withdrew: Covid-19 adverse event64
Withdrew: Lack of efficacy25
Withdrew: Study terminated by sponsor10
Withdrew: Investigator discretion21
Withdrew: Withdrawal by subject5230
Withdrew: Lost to follow-up811
Withdrew: Other22

Outcome measures

PrimaryLeast Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Average FEV1 AUC0-12h was defined as AUC over 12 hours of the FEV1, divided by 12 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.

Time frame:
Baseline (40 minutes before first administration on Day 1) and Week 12
Reported as:
Least squares mean · liters
Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12
litersEnsifentrinePlacebo
Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 120.0480 ± 0.00941-0.0462 ± 0.01236
Statistical analysis
  • Ensifentrine vs Placebo · ANCOVA · p = <0.0001 (The analysis of covariance (ANCOVA) model was used to model the change from baseline FEV1 to average FEV1 AUC0-12h with treatment, region, background medication strata and smoking strata as fixed effects and baseline FEV1 as covariate.) · Ls mean difference: 0.0941 · 95% CI 0.0647 to 0.1236
SecondaryLS Mean Change From Baseline FEV1 to Peak FEV1 at Day 1 and Weeks 6, 12 and 24

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Peak FEV1 is the maximum value in the 4 hours after dosing. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (40 minutes before first administration on Day 1), post-dose on Day 1, Weeks 6, 12, and 24
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FEV1 to Peak FEV1 at Day 1 and Weeks 6, 12 and 24
litersEnsifentrinePlacebo
Day 1 (Post-dose)0.2369 ± 0.006010.0801 ± 0.00784
Week 60.2158 ± 0.009690.0636 ± 0.01276
Week 120.1945 ± 0.010120.0482 ± 0.01349
Week 240.1957 ± 0.010990.0434 ± 0.01475
SecondaryLS Mean Change From Baseline to the Mean Weekly Evaluating-Respiratory Symptoms (E-RS) Total Score at Weeks 6, 12 and 24

The E-RS scale consists of 11 questions, with 3 sub-domains of: breathlessness, cough and sputum, and chest symptoms. The E-RS sub-domain score was calculated as the sum from the relevant questions. The E-RS total score was derived as the sum of the raw scores of the 11 items ranging from 0 to 40. Higher scores indicates severe respiratory symptoms. Scores were derived weekly as the mean over 7 days prior to the visit, using only days where data was recorded. The E-RS was collected daily by electronic diary (e-diary). Baseline is the mean over the 7 days prior to the first intake of study medication, using only days where data was recorded.

Time frame:
Baseline (average of 7 days before first administration on Day 1) and Weeks 6, 12, and 24
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline to the Mean Weekly Evaluating-Respiratory Symptoms (E-RS) Total Score at Weeks 6, 12 and 24
units on a scaleEnsifentrinePlacebo
Week 6-1.938 ± 0.2086-0.614 ± 0.2763
Week 12-2.051 ± 0.2245-1.161 ± 0.2963
Week 24-2.146 ± 0.2557-1.529 ± 0.3365
SecondaryLS Mean Change From Baseline in the St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 6, 12 and 24

The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Score ranging from 0 to 100 and higher scores indicated a worse outcome. Baseline is the score calculated on Day 1 prior to 4 hour post-dose spirometry.

Time frame:
Baseline (40 minutes before first administration on Day 1) and Weeks 6, 12, and 24
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline in the St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 6, 12 and 24
units on a scaleEnsifentrinePlacebo
Week 6-3.602 ± 0.5902-1.890 ± 0.7692
Week 12-4.019 ± 0.6171-2.942 ± 0.8168
Week 24-4.532 ± 0.6840-4.054 ± 0.9084
SecondaryLS Mean Change From Baseline FEV1 to Morning Trough FEV1 at Weeks 6, 12 and 24

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Morning trough FEV1 was the last value collected prior to the morning dose. Baseline FEV1 is the mean of the two measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (40 minutes before first administration on Day 1) and Weeks 6, 12, and 24
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FEV1 to Morning Trough FEV1 at Weeks 6, 12 and 24
litersEnsifentrinePlacebo
Week 60.0177 ± 0.00899-0.0261 ± 0.01181
Week 120.0057 ± 0.00957-0.0435 ± 0.01266
Week 24-0.0066 ± 0.01006-0.0318 ± 0.01323
SecondaryLS Mean Change From Baseline in Average FEV1 Area Under the Curve Over 4 Hours (AUC0-4h) at Day 1 and Weeks 6, 12 and 24

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Average FEV1 AUC0-4h was defined as area under the curve over 4 hours of the FEV1, divided by 4 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on Day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (40 minutes before first administration on Day 1), post-dose on Day 1, Weeks 6, 12, and 24
Reported as:
Least squares mean · liters
LS Mean Change From Baseline in Average FEV1 Area Under the Curve Over 4 Hours (AUC0-4h) at Day 1 and Weeks 6, 12 and 24
litersEnsifentrinePlacebo
Day 1 (Post-dose)0.1556 ± 0.005270.0063 ± 0.00686
Week 60.1357 ± 0.00932-0.0082 ± 0.01209
Week 120.1148 ± 0.00943-0.0209 ± 0.01260
Week 240.1148 ± 0.01036-0.0248 ± 0.01381
SecondaryPercentage of SGRQ Responders at Weeks 6, 12 and 24

The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Responder was a patient with an improvement from baseline in SGRQ total score of 4 or more. Percentage of SGRQ responders are reported.

Time frame:
Weeks 6, 12 and 24
Reported as:
Number · percentage of patients
Percentage of SGRQ Responders at Weeks 6, 12 and 24
percentage of patientsEnsifentrinePlacebo
Week 644.039.5
Week 1245.243.0
Week 2445.450.3
SecondaryLS Mean Change From Baseline to the Mean Weekly Rescue Medication Use at Weeks 6, 12 and 24

Use of rescue medication (albuterol/salbutamol) per week was calculated as the LS mean use daily over 7 days. Daily rescue medication use was collected in an e-diary throughout the study. Baseline is the mean over the 7 days prior to the first intake of study medication, calculated as the sum of puffs taken, divided by number of days data has been recorded.

Time frame:
Baseline (average of 7 days before first administration on Day 1) and Weeks 6, 12, and 24
Reported as:
Least squares mean · avg number of rescue medication puffs
LS Mean Change From Baseline to the Mean Weekly Rescue Medication Use at Weeks 6, 12 and 24
avg number of rescue medication puffsEnsifentrinePlacebo
Week 6-0.530 ± 0.0883-0.191 ± 0.1165
Week 12-0.573 ± 0.0745-0.288 ± 0.0976
Week 24-0.485 ± 0.0871-0.346 ± 0.1143
SecondaryLS Mean Transition Dyspnea Index (TDI) Questionnaire Total Score at Weeks 6, 12 and 24

The TDI is a questionnaire that focused on 3 sub-domains: functional impairment, magnitude of task and magnitude of effort. Sub-domain score was calculated as the sum from the related questions. Total score was calculated as the sum of the sub-domain scores. The TDI measures the change in dyspnea severity from the baseline as measured by the baseline dyspnea index. It was rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement). Higher scores indicate better outcome. Change from baseline was assessed with the Baseline Dyspnea Index.

Time frame:
Weeks 6, 12 and 24
Reported as:
Least squares mean · units on a scale
LS Mean Transition Dyspnea Index (TDI) Questionnaire Total Score at Weeks 6, 12 and 24
units on a scaleEnsifentrinePlacebo
Week 61.6 ± 0.120.9 ± 0.16
Week 121.8 ± 0.131.2 ± 0.18
Week 242.2 ± 0.151.3 ± 0.20
SecondaryLS Mean Change From Baseline FEV1 to Evening Trough FEV1 at Week 12

Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Evening trough FEV1 was the value collected at 12 hours post-morning dose and prior to the evening dose. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing, that is, \<=40 minutes pre-dose on day 1. Spirometry assessments were performed in accordance with ATS/ERS guidelines.

Time frame:
Baseline (40 minutes before first administration on Day 1) and Week 12
Reported as:
Least squares mean · liters
LS Mean Change From Baseline FEV1 to Evening Trough FEV1 at Week 12
litersEnsifentrinePlacebo
LS Mean Change From Baseline FEV1 to Evening Trough FEV1 at Week 12-0.0246 ± 0.01079-0.0783 ± 0.01358

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from the first dose of study treatment up to 10 days after the final study visit at Week 24, approximately 25 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ensifentrine4/498 (0.8%)28/498 (5.6%)68/498 (13.7%)
Placebo1/291 (0.3%)17/291 (5.8%)46/291 (15.8%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventEnsifentrinePlacebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders10/4985/291
PneumoniaInfections and infestations2/4984/291
COVID-19 pneumoniaInfections and infestations2/4982/291
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/4980/291
BronchiectasisRespiratory, thoracic and mediastinal disorders0/4981/291
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/4981/291
PneumothoraxRespiratory, thoracic and mediastinal disorders0/4981/291
Respiratory failureRespiratory, thoracic and mediastinal disorders0/4981/291
Clostridium difficile infectionInfections and infestations0/4981/291
Septic shockInfections and infestations0/4981/291
Most frequent other events
Showing 10 of 13
Most frequent other events
EventEnsifentrinePlacebo
COVID-19Infections and infestations16/49810/291
HeadacheNervous system disorders10/4987/291
NasopharyngitisInfections and infestations9/4983/291
Urinary tract infectionInfections and infestations7/4985/291
Back painMusculoskeletal and connective tissue disorders8/4985/291
DiarrheaGastrointestinal disorders8/4982/291
DyspneaRespiratory, thoracic and mediastinal disorders3/4984/291
Angina pectorisCardiac disorders1/4984/291
Tooth AbcessInfections and infestations0/4984/291
VertigoEar and labyrinth disorders1/4983/291

Baseline characteristics

All patients randomized set included all patients in the enrolled set who were randomized to study medication.

Age, Continuous
Age, Continuous(years)EnsifentrinePlaceboTotal
Mean65.0 ± 7.3865.3 ± 7.3065.1 ± 7.35
Sex: Female, Male
Sex: Female, Male(Participants)EnsifentrinePlaceboTotal
Female254153407
Male245138383
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EnsifentrinePlaceboTotal
American Indian or Alaska native101
Asian112
Black or African American241135
White472276748
Other134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EnsifentrinePlaceboTotal
Hispanic or Latino261440
Not Hispanic or Latino473277750
Region of Enrollment
Region of Enrollment(participants)EnsifentrinePlaceboTotal
Belgium415
Bulgaria7853131
Canada7613
Denmark314
Estonia18220
Hungary322052
Poland382058
Slovakia13518
Spain25934
United States281174455
08

Study locations

130 sites
  • Wright Clinical Research, LLC
    Alabaster, Alabama 35007, United States
  • SEC Clinical Research
    Andalusia, Alabama 36420, United States
  • Jasper Summit Research LLC
    Jasper, Alabama 35501, United States
  • Pulmonary Associates Clinical Trials
    Phoenix, Arizona 85006, United States
  • Elite Clinical Studies LLC
    Phoenix, Arizona 85018, United States
  • Clinical Research Institute of Arizona, LLC
    Sun City West, Arizona 85375, United States
  • Premier Medical Group
    Bakersfield, California 93309, United States
  • Antelope Valley Clinical Trials
    Lancaster, California 93534, United States
  • Downtown LA Research Center, Inc.
    Los Angeles, California 90017, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • California Medical Research Associates
    Northridge, California 91324, United States
  • Center for Clinical Trials of Sacramento, Inc.
    Sacramento, California 95823, United States
  • Integrated Research Center
    San Diego, California 92117, United States
  • Institute of HealthCare Assessment, Inc.
    San Diego, California 92120, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80301, United States
  • Innovative Research of West Florida
    Clearwater, Florida 33756, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Accel Research Sites - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Medical Research of Central Florida
    Leesburg, Florida 34748, United States
  • Axcess Medical Research
    Loxahatchee Groves, Florida 13005, United States
  • ProCare Clinical Research
    Miami Gardens, Florida 33014, United States
  • Research Institute of South Florida
    Miami, Florida 33173, United States
  • Advanced Medical Research Institute
    Miami, Florida 33174, United States
  • Clinical Trials of Florida. LLC
    Miami, Florida 33186, United States
  • South Medical Research Group, Inc.
    Miami, Florida 33186, United States
  • HMD Research, LLC
    Orlando, Florida 32819, United States
  • Florida Institute for Clinical Research
    Orlando, Florida 32825, United States
  • Coastal Pulmonary Critical Care
    Saint Petersburg, Florida 33704, United States
  • Pasadena Center for Medical Research, LLC
    Saint Petersburg, Florida 33707, United States
  • Sarasota Clinical Research
    Sarasota, Florida 34239, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33606, United States
  • Clinical Research Trials of Florida, Inc.
    Tampa, Florida 33607, United States
  • Florida Pulmonary Research Institute, LLC
    Winter Park, Florida 32789, United States
  • AMR New Orleans
    New Orleans, Louisiana 70119, United States
  • Genesis Clin RES& Consulting
    Fall River, Massachusetts 02723, United States
  • Minnesota Lung Center
    Edina, Minnesota 55435, United States
  • Minnesota Lung Center
    Woodbury, Minnesota 55125, United States
  • Midwest Chest Consultants
    Saint Charles, Missouri 63301, United States
  • Montana Medical Research Inc.
    Missoula, Montana 59808, United States
  • CHEAR Center LLC
    Bronx, New York 10455, United States
  • Mid Hudson Medical Research
    New Windsor, New York 12553, United States
  • Carolina Clinical Research
    Charlotte, North Carolina 28273, United States
  • American Health Research
    Charlotte, North Carolina 28277, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • PharmQuest LLC
    Greensboro, North Carolina 27408, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Clinical Research of Lake Norman
    Mooresville, North Carolina 28117, United States
  • Carolina Research Center, Inc.
    Shelby, North Carolina 28150, United States
  • Aventiv Research Inc.
    Columbus, Ohio 43213, United States
  • Remington Davis Clinical Research
    Columbus, Ohio 43215, United States
  • Aventiv Research
    Dublin, Ohio 43106, United States
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
  • Velocity Clinical Research, Medford (Crisor, LLC)
    Medford, Oregon 97504, United States
  • Safe Harbor Clinical Research
    East Providence, Rhode Island 02914, United States
  • VitaLink Research Anderson
    Anderson, South Carolina 29621, United States
  • Lowcountry Lung and Critical Care, P.A.
    Charleston, South Carolina 29406, United States
  • VitaLink Research Columbia
    Columbia, South Carolina 29204, United States
  • Piedmont Research Partners
    Fort Mill, South Carolina 29707, United States
  • VitaLink Research Gaffney
    Gaffney, South Carolina 29340, United States
  • VitaLink Research - Greenville
    Greenville, South Carolina 29615, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • VitaLink Research Spartanburg
    Spartanburg, South Carolina 29303, United States
  • CU Pharmaceutical Research
    Union, South Carolina 29379, United States
  • MultiSpecialty Clinical Research, Inc.
    Johnson City, Tennessee 37601, United States
  • New Phase Research Development
    Knoxville, Tennessee 37909, United States
  • PnP Research
    Amarillo, Texas 79106, United States
  • TTS Research
    Boerne, Texas 78006, United States
  • Corsicana Medical Research, PLLC
    Corsicana, Texas 75110, United States
  • Houston Pulmonary and Sleep Allergy and Asthma Associates
    Cypress, Texas 77429, United States
  • Metroplex Pulmonary and Sleep Center
    McKinney, Texas 75069, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Element Research Group
    San Antonio, Texas 78258, United States
  • Sherman Clinical Research
    Sherman, Texas 75092, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • UZA
    Edegem, 2650, Belgium
  • C.H.R. de la Citadelle
    Liège, 4000, Belgium
  • Private Practice RESPISOM Namur
    Namur, 5101, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • MHAT 'Puls' AD
    Blagoevgrad, 2700, Bulgaria
  • Medical Centre "Asklepii", OOD
    Dupnitsa, 2600, Bulgaria
  • MHAT 'Dr. Stamen Iliev', AD
    Montana, 3400, Bulgaria
  • SHATPPD - Pazardzhik, EOOD
    Pazardzhik, 4400, Bulgaria
  • SHATPD Pernik
    Pernik, 2305, Bulgaria
  • Medical Center- Prolet Ltd
    Ruse, 7000, Bulgaria
  • SHATPPD-Ruse EOOD
    Ruse, 7002, Bulgaria
  • University First MHAT-Sofia, "St. Joan Krastitel" EAD
    Sofia, 1142, Bulgaria
  • Fifth MHAT - Sofia EAD
    Sofia, 1233, Bulgaria
  • NMTH "Tsar Boris III"
    Sofia, 1233, Bulgaria
  • MHAT "Lyulin", EAD
    Sofia, 1336, Bulgaria
  • DCC "Alexandrovska", EOOD
    Sofia, 1431, Bulgaria
  • Diagnostic Consultation Center CONVEX EOOD
    Sofia, 1680, Bulgaria
  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
    Stara Zagora, 6000, Bulgaria
  • Medical Center "ResearchExpert", OOD
    Varna, 9000, Bulgaria
  • MC "Tara", OOD
    Veliko Tarnovo, 5000, Bulgaria
  • SHATPPD "Dr. Treyman" EOOD
    Veliko Tarnovo, 5000, Bulgaria
  • SHATPPD - Vratsa, EOOD
    Vratsa, 3000, Bulgaria
  • ALTA Clinical Research Inc.
    Edmonton, Alberta T5A 4L8, Canada

Showing the first 100 of 130 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in May 2022, 19 months.

Results were first posted in Jul 2023, 1 year 2 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 19 months is close to that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Sep 9, 2020
StartActual
Sep 22, 2020
Primary completionActual
May 3, 2022
CompletionActual
Jul 6, 2022
Results first posted
Jul 24, 2023
Last update
Oct 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04542057
Lead sponsor
Verona Pharma plc
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Sep 22, 2020
Primary completion
May 3, 2022
Completion
Jul 6, 2022
Results posted
Jul 24, 2023
Last update
Oct 16, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion